Index Investing News
Sunday, May 25, 2025
No Result
View All Result
  • Login
  • Home
  • World
  • Investing
  • Financial
  • Economy
  • Markets
  • Stocks
  • Crypto
  • Property
  • Sport
  • Entertainment
  • Opinion
  • Home
  • World
  • Investing
  • Financial
  • Economy
  • Markets
  • Stocks
  • Crypto
  • Property
  • Sport
  • Entertainment
  • Opinion
No Result
View All Result
Index Investing News
No Result
View All Result

Starboard may be poised to build value amicably at contract research firm Fortrea

by Index Investing News
October 22, 2023
in Markets
Reading Time: 4 mins read
A A
0
Home Markets
Share on FacebookShare on Twitter


Sanjeri | E+ | Getty Images

Company: Fortrea Holdings (FTRE)

Business: Fortrea Holdings is a global contract research organization, or CRO, that provides clinical development and patient access solutions to the life sciences industry. CROs work with drug companies through all stages of the drug development process, from drug discovery and preclinical development to Phase I through IV post-approval work. The company was originally part of Covance from 1997 to 2015, where it had central lab preclinical and Phase I through IV clinical development capabilities. Covance was acquired by Labcorp in 2015, and Labcorp (LH) spun out Fortrea in July 2023.

Stock Market Value: $2.6B ($29.77 per share)

Activist: Starboard Value

Percentage Ownership:  8.75%

Average Cost: $28.42

Activist Commentary: Starboard has made 113 prior 13D filings and has an average return of 26.61% versus 11.88% for the S&P 500 over the same period. Of these 113 filings, 13 have been on companies in the health-care sector, where Starboard has an average return of 38.64% versus 13.23% for the S&P 500 over the same period.

What’s happening?

On Oct. 17, Starboard reported an 8.75% position in Fortrea Holdings.

Behind the scenes

Fortrea was spun out from Labcorp on July 3, as a Phase I through IV clinical development business. The company is one of the top seven contract research organizations that control 80% of the market. Over the years, drug companies have spent an increasing amount of money on research and development. With a material portion of that outsourced, the CRO industry has grown accordingly. So, there are strong secular tailwinds driving growth for the CRO industry, but to be a successful contract research organization, it helps to have global scale. Fortrea has operations in more than 90 countries with a focus on more than 20 therapeutic areas, which has allowed them to conduct over 5,000 trials over the last five years. However, despite having global reach and scale, the company’s adjusted 2023 earnings before interest, taxes, depreciation and amortization margins are only 9% (with projected 2024 margins of 13%), significantly below the peer median of 18%. This is not unusual for a company that has recently been spun out of a larger company as it could be saddled with a bloated cost structure in the spinout and could have been somewhat neglected operationally as a smaller part of a large company.  

So, now it is in a position to be run more efficiently with management solely focused on the CRO business. The crucial factor in achieving this is having the right CEO for the job, and Fortrea has that. In January, Tom Pike joined Labcorp as president and CEO of its Drug Development Clinical Development business unit and retained his CEO seat at Fortrea, upon completion of the spin-off. Pike has a track record for improving CRO profitability. When he was CEO at Fortrea peer IQVIA (formerly known as Quntiles), he increased margins by 425 basis points between 2012 and 2016, and led the stock to substantially outperform the market by 48% over that time. He has already committed to increasing margins at Fortrea to 13% from 9%, but this still falls short of peer performance. Starboard thinks that the company can reach pure margin levels of 18%. The firm has a great deal of experience helping portfolio companies run more efficiently and improve margins either as an active shareholder or member of the board.

With Pike as CEO and margin guidance going in the right direction, we expect Starboard will be an engaged shareholder here and look for a board seat only if things do not progress as planned. In that case, there is no reason why this would not be amicable. Both Starboard and Pike share the same views regarding margin improvement and seem to be rowing in the same direction. With peer margins and peer multiples, Starboard sees this as a $47 to $72 stock.

Finally, there may also be compelling strategic opportunities to create shareholder value. Private equity firms and strategics have been frequent acquirers of CRO assets and recent transactions have been at higher multiples, with a median of 14x EBITDA. Moreover, this is a consolidating industry right now. Elliott Management recently partnered with Patient Square Capital and Veritas Capital to acquire Fortrea peer Syneos Health Inc (SYNH) for $7.1 billion. That acquisition is expected to close in the second half of 2023. Elliott also just got management of Catalent, an outsourced manufacturer in the pharma industry, to pursue a strategic review. Once margins are improved and the company is running efficiently, there may be significant private equity and strategic interest here as well.

Ken Squire is the founder and president of 13D Monitor, an institutional research service on shareholder activism, and the founder and portfolio manager of the 13D Activist Fund, a mutual fund that invests in a portfolio of activist 13D investments. Fortrea Holdings is owned in the fund.



Source link

Tags: amicablybuildcontractfirmFortreaPoisedResearchStarboard
ShareTweetShareShare
Previous Post

ICICI Bank Q2 results: PAT soars 36% YoY to Rs 10,261 crore, NII grows 24%

Next Post

Johnny Nelson: Isaac Chamberlain vs Mikael Lawal ‘like a volcano waiting to erupt’ | Boxing News

Related Posts

Prime Wall Road analysts favor these shares for the lengthy haul

Prime Wall Road analysts favor these shares for the lengthy haul

by Index Investing News
May 25, 2025
0

Idrees Abbas | SOPA Photographs | Lightrocket | Getty PhotographsThe rising U.S. funds deficit is on the forefront of traders'...

ValueAct takes a stake in Rocket Cos. How the activist might assist raise shares

ValueAct takes a stake in Rocket Cos. How the activist might assist raise shares

by Index Investing News
May 24, 2025
0

FILE PHOTO: A banner celebrating Rocket Firms Inc., the mother or father firm of U.S. mortgage lender Quicken Loans, IPO...

Costco (COST) all set to report Q3 2025 earnings. Right here’s what to anticipate

Costco (COST) all set to report Q3 2025 earnings. Right here’s what to anticipate

by Index Investing News
May 23, 2025
0

Costco Wholesale Company (NASDAQ: COST) has delivered a formidable efficiency within the first half of FY25, aided by robust membership...

Goal Company (TGT): A take a look at how the retailer is navigating a troublesome atmosphere

Goal Company (TGT): A take a look at how the retailer is navigating a troublesome atmosphere

by Index Investing News
May 24, 2025
0

Shares of Goal Company (NYSE: TGT) stayed pink on Friday. The inventory has dropped 23% over the previous three months....

The Massive Lovely Bitcoin Breakout

The Massive Lovely Bitcoin Breakout

by Index Investing News
May 23, 2025
0

Bitcoin (BTC) broke $111,000 yesterday, an all-time excessive. Supply: coingecko.com And since everybody is aware of I’m a crypto bull,...

Next Post
Johnny Nelson: Isaac Chamberlain vs Mikael Lawal ‘like a volcano waiting to erupt’ | Boxing News

Johnny Nelson: Isaac Chamberlain vs Mikael Lawal 'like a volcano waiting to erupt' | Boxing News

Will $SHIB Price Rally to alt=

Will $SHIB Price Rally to $0.000008?

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED

Shamima Begum slammed for ‘sham’ remorse as BBC faces fury for giving ‘terrorist’ ISIS bride a podcast

Shamima Begum slammed for ‘sham’ remorse as BBC faces fury for giving ‘terrorist’ ISIS bride a podcast

January 22, 2023
Worth of electrical energy to rise by lower than deliberate

Worth of electrical energy to rise by lower than deliberate

December 25, 2024
El-Erian warns of ‘price of dwelling disaster,’ says Fed price hikes might trigger recession

El-Erian warns of ‘price of dwelling disaster,’ says Fed price hikes might trigger recession

March 28, 2022
Good News on State Taxes

Good News on State Taxes

October 20, 2022
Berkshire Hathaway 2022 annual report

Berkshire Hathaway 2022 annual report

February 26, 2023
Adani to sell 90% stake in fin services to Bain Capital for Rs 1,440 cr

Adani to sell 90% stake in fin services to Bain Capital for Rs 1,440 cr

July 23, 2023
Sebi: Companies say Sebi’s new rules increase compliance load

Sebi: Companies say Sebi’s new rules increase compliance load

August 1, 2023
Former legendary Liverpool captain Ron Yeats dies aged 86

Former legendary Liverpool captain Ron Yeats dies aged 86

September 7, 2024
Index Investing News

Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.

  • 1717575246.7
  • Browse the latest news about investing and more
  • Contact us
  • Cookie Privacy Policy
  • Disclaimer
  • DMCA
  • Privacy Policy
  • Terms and Conditions
  • xtw18387b488

Copyright © 2022 - Index Investing News.
Index Investing News is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • World
  • Investing
  • Financial
  • Economy
  • Markets
  • Stocks
  • Crypto
  • Property
  • Sport
  • Entertainment
  • Opinion

Copyright © 2022 - Index Investing News.
Index Investing News is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In